Cargando…
Basis for Immunotherapy for Treatment of Meningiomas
Meningiomas are common tumors that account for approximately one third of CNS tumors diagnosed every year. They are classified by the World Health Organization in grades I-III. Higher grades have an increased rate of growth, invasiveness, rate of recurrence, and worse outcomes than lower grades. Mos...
Autores principales: | Garzon-Muvdi, Tomas, Bailey, Destiny D., Pernik, Mark N., Pan, Edward |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483661/ https://www.ncbi.nlm.nih.gov/pubmed/32982948 http://dx.doi.org/10.3389/fneur.2020.00945 |
Ejemplares similares
-
Metastatic high-grade meningioma: A case report and review of risk factors for metastasis
por: Bailey, Destiny D, et al.
Publicado: (2023) -
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
por: Traylor, Jeffrey I., et al.
Publicado: (2021) -
Case report: Meningioma associated with meningioangiomatosis mimicking invasive meningioma
por: Ge, Rong, et al.
Publicado: (2023) -
Case report: Clinical report of co-occurrence of pituitary adenoma and meningioma in the sellar region after meningioma treatment
por: Lu, Wang, et al.
Publicado: (2022) -
Editorial: Atypical and malignant meningioma: Advances in pathophysiology, imaging and treatment
por: Ahmad, Maleeha, et al.
Publicado: (2022)